# OnCo record nct04819100 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04819100/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04819100", "NCT04819100" ;
  schema:name "A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)"@en ;
  schema:alternateName "LIBRETTO-432"@en ;
  schema:description "A phase 3 trial of Selpercatinib in non-small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04819100/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04819100> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-12-20" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/resectable-nsclc/>, <https://onco.cc/cancers/ret-fusion-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04819100-n-engl-j-med-2026/> .